- Scanlon K.J., Newman, E.M., Lu Y., and Priest D.G. Biochemical basis for cisplatin and 5-Fura synergism in human ovarian carcinoma cells. Proc. Nat’l. Acad. Sci. (USA) 83:8923-8925, 1986.
- Scanlon, K.J. and Kashani-Sabet, M. Elevated expression of dTMP synthase cycle genes in cisplatin-resistant human ovarian carcinoma cells. Proc. Nat’l. Acad. Sci (USA) 85:650-653, 1988.
- Scanlon, K.J., Jiao, L., Funato, T., Wang, W., Tone, T., Rossi, J.J., and Kashani-Sabet, M. Ribozyme-mediated cleavage of c-fos mRNA reduces gene expression of DNA synthesis enzymes and metallothionein. Proc. Nat’l. Acad. Sci. (USA) 88:10592-10595, 1991.
- Scanlon, K.J., Ishida, H., and Kashani-Sabet, M. Reversal of the multi-drug resistant phenotype by a fos ribozyme. Proc. Nat’l. Acad. Sci. (USA) 91:11123-11127, 1994.
- Scanlon, K.J. Antisense and Ribozyme Therapy, Chapter 91, (2005) Cancer Handbook 1st Edition, Edited by Malcolm R. Alison at John Wiley & Sons, Ltd.
- Harvard University: Video on Non-Government Funding of Medical Research by the Pharmaceutical Industry and Investors. (vimeo.com/video/151186756/).
- Post-Doctoral Fellow, Cancer Research (Pharmacology Department), Yale University School of Medicine
- Ph.D., Molecular Biology, University of London, Royal Holloway College
- B.A., Biology-Chemistry, Sacred Heart University
Research & Teaching Interests
Dr. Scanlon’s teaching interest comes from his 15 years in the investment community. He educates entrepreneurs in understanding the investment process with his new course (ENTR 4505). To date, hehas helped ~60 university technology companies and trained ~300 students. The course teaches how to develop a product, build teams, create business models and get financed from the points of view of the entrepreneur, investor, and customer. Students are invited to attend the monthly angel investor meetings on campus.
Industry & Academic Experience
Dr. Scanlon was faculty at UCLA, School of Management, and taught a course on entrepreneurship. He was CEO of Melanoma Diagnostics (sold to Myriad Genetics). He served as Chairman of the Pasadena Angels Investment Group (Pasadena, CA), a top10 angel group in the U.S. He was also a senior executive at Schering in Berlin, Germany. He has been a judge for both MassChallenge and Mass Science Innovation Day.
Services to the Profession
Dr. Scanlon was Co-Founder & Co-Editor of Cancer Gene Therapy (Nature) and is now Emeritus Editor.
He has also been Editor of Therapeutic Applications of Ribozymes in Molecular Medicine and Editor of Human Gene Therapy, Schering Research Foundation (Springer).
He has served on several scientific editorial boards, served on several biotechnology company boards and on academic advisory boards.
Dr. Scanlon has seven issued patents on cancer detection, treatment and modulating drug/radiation resistance in patients.
Awards & Recognition
Dr. Scanlon received the Paul Martini Medical Research Award in Germany for his work on cancer. He was also named a Leukemia Society Scholar and Leukemia Society of America Fellow. In addition, Los Angeles TechWeek acknowledged Dr. Scanlon as an established community leader that has significantly impacted the local business and technology sectors.